No evidence for Ruxolitinib treatment being a potential risk factor for secondary primary malignancies (SPM) in 201 BCR/ABL-negative myeloproliferative neoplasm patients
Wille K, Sadjadian P, Becker T, Kolatzki V, Fuchs C, Griesshammer M (2019)
In: ONCOLOGY RESEARCH AND TREATMENT., 42(Suppl. 4). Basel: Karger: 71.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Wille, K.;
Sadjadian, P.;
Becker, T.;
Kolatzki, V;
Fuchs, ChristianeUniBi 
;
Griesshammer, M.
;
Griesshammer, M.Erscheinungsjahr
2019
Titel des Konferenzbandes
ONCOLOGY RESEARCH AND TREATMENT
Band
42
Ausgabe
Suppl. 4
Seite(n)
71
ISSN
2296-5270
eISSN
2296-5262
Page URI
https://pub.uni-bielefeld.de/record/2946520
Zitieren
Wille K, Sadjadian P, Becker T, Kolatzki V, Fuchs C, Griesshammer M. No evidence for Ruxolitinib treatment being a potential risk factor for secondary primary malignancies (SPM) in 201 BCR/ABL-negative myeloproliferative neoplasm patients. In: ONCOLOGY RESEARCH AND TREATMENT. Vol 42. Basel: Karger; 2019: 71.
Wille, K., Sadjadian, P., Becker, T., Kolatzki, V., Fuchs, C., & Griesshammer, M. (2019). No evidence for Ruxolitinib treatment being a potential risk factor for secondary primary malignancies (SPM) in 201 BCR/ABL-negative myeloproliferative neoplasm patients. ONCOLOGY RESEARCH AND TREATMENT, 42, 71. Basel: Karger.
Wille, K., Sadjadian, P., Becker, T., Kolatzki, V, Fuchs, Christiane, and Griesshammer, M. 2019. “No evidence for Ruxolitinib treatment being a potential risk factor for secondary primary malignancies (SPM) in 201 BCR/ABL-negative myeloproliferative neoplasm patients”. In ONCOLOGY RESEARCH AND TREATMENT, 42:71. Basel: Karger.
Wille, K., Sadjadian, P., Becker, T., Kolatzki, V., Fuchs, C., and Griesshammer, M. (2019). “No evidence for Ruxolitinib treatment being a potential risk factor for secondary primary malignancies (SPM) in 201 BCR/ABL-negative myeloproliferative neoplasm patients” in ONCOLOGY RESEARCH AND TREATMENT, vol. 42, (Basel: Karger), 71.
Wille, K., et al., 2019. No evidence for Ruxolitinib treatment being a potential risk factor for secondary primary malignancies (SPM) in 201 BCR/ABL-negative myeloproliferative neoplasm patients. In ONCOLOGY RESEARCH AND TREATMENT. no.42 Basel: Karger, pp. 71.
K. Wille, et al., “No evidence for Ruxolitinib treatment being a potential risk factor for secondary primary malignancies (SPM) in 201 BCR/ABL-negative myeloproliferative neoplasm patients”, ONCOLOGY RESEARCH AND TREATMENT, vol. 42, Basel: Karger, 2019, pp.71.
Wille, K., Sadjadian, P., Becker, T., Kolatzki, V., Fuchs, C., Griesshammer, M.: No evidence for Ruxolitinib treatment being a potential risk factor for secondary primary malignancies (SPM) in 201 BCR/ABL-negative myeloproliferative neoplasm patients. ONCOLOGY RESEARCH AND TREATMENT. 42, p. 71. Karger, Basel (2019).
Wille, K., Sadjadian, P., Becker, T., Kolatzki, V, Fuchs, Christiane, and Griesshammer, M. “No evidence for Ruxolitinib treatment being a potential risk factor for secondary primary malignancies (SPM) in 201 BCR/ABL-negative myeloproliferative neoplasm patients”. ONCOLOGY RESEARCH AND TREATMENT. Basel: Karger, 2019.Vol. 42. 71.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar